Skip navigation

I want it now

Relenza landmark
Useful answers

Not just the words of a child in one of its phases, but actually a much more pervasive sentiment. New interventions, including pharmaceutical interventions, are often judged on the basis of trials with relatively small numbers of patients. The average is said to be about 1,500, though there is a trend for much larger trials.

Of course the regulatory bodies see all the information they need, but the poor bloody infantry have to make do with "data on file", or abstracts, or "the paper will be available shortly in X, Y or Z journal". But the poor bloody infantry have learned to be more sceptical, and want to see the information for themselves, let alone at health authority or primary care group level.

Relenza landmark


Relenza is a landmark, not because it is the first NICE report, but because the information on which the evaluation was based is up there on the web for all to see. We review it in this issue of Bandolier . Why can't we have something similar at every new drug launch?

Useful answers


It is said that when the USA went into space, they found that ballpoint pens didn't work, so spent £25 million inventing one that did. You can buy a zero-g pen for Christmas! The Russians just used a pencil.

Reviewers should remember that those of us who use reviews want a simple answer fast. We are the Russians, who don't have the super-pens, just a pencil and the back of an envelope. So use statistical outputs by all means, but just tell us the answer in simple, plain English!


next story in this issue